Amarin Corporation plc
HealthcareNASDAQ:AMRN · NASDAQ Global Market
+$0.34 today
Vol 0.08M · Avg 0.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-8.4%
avg 91.9%
ROIC
-2.9%
avg -25.3%
ROA
-5.8%
avg -21.0%
Analysis
ROIC is currently the strongest return metric at -2.9% versus its period average of -25.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Aaron D. Berg | Chief Executive Officer, President & Director | $1.66M | — | 63 | $120,566.00 | 0.58% |
Steven Ketchum | Executive Vice President, President of Research & Development and Chief Scientific Officer | $1.49M | — | 61 | $36,060.00 | 0.17% |
David Keenan | Executive Vice President & Chief Operating Officer | $1.19M | — | 58 | $30,060.00 | 0.15% |
Jonathan N. Provoost | Executive Vice President, Chief Legal & Compliance Officer and Secretary | $931,207.00 | — | 56 | $8,013.00 | 0.04% |
Peter Fishman | Senior Vice President & Chief Financial Officer | $750,989.00 | — | 42 | $6,282.00 | 0.03% |
Eric Boothe | Senior Vice President of Corporate Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +7.8% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +7.8% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Silence Therapeutics plc
NASDAQ:SLN
$316.00M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Cellectis S.A.
NASDAQ:CLLS
$310.29M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$296.96M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages AMRN?
Amarin Corporation plc (AMRN) lists 6 active executives. The top listed executive is Aaron D. Berg, Chief Executive Officer, President & Director.
Are AMRN insiders buying or selling?
Recent insider activity shows net buying of $10.26M.
Explore More
Continue the stock analysis
Jump to another research area for this company.